Compare Rigetti Computing Inc (RGTI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Rigetti Computing Inc trades at $15.2 (market cap $5.08B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| RGTI | XBI | |
|---|---|---|
Market Cap | $5.08B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $56.34 | $164.28 |
52-Week Low | $12.90 | $85.16 |
Enterprise Value | $4.67B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, while showing bearish technical signals with 17 sell indicators versus 5 buy signals. The company maintains strong analyst support with 85.7% buy ratings and a $32.67 consensus price target, despite posting significant losses (-$216.21M net income) and negative margins. Recent news highlights Rigetti's $569M cash position and government contracts supporting its quantum computing roadmap.
RGTI offers substantial upside potential based on analyst targets but carries high risk due to persistent losses and negative profitability metrics. The stock's investment thesis hinges on successful quantum technology commercialization, with current valuation reflecting speculative growth expectations rather than fundamental performance.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
